Skip to content
Nonprofiteer
← All organizations

FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND

EIN 98-0407553 SWITZERLAND

Revenue 2024
$49,306,331
Expenses 2024
$56,828,646

Program services were 81.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

As filed

Subsection
03
NTEE code
H80
Classification
2100
Street
GRANDSACONNEX

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

Mission

FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES.

Activities or mission (Part I)

THE DEVELOPMENT AND IMPLEMENTATION OF NEW, LOW COST DIAGNOSTICS FOR INFECTIOUS DISEASES FOR USE IN LOW-RESOURCE AREAS.

  • See schedule O

    Expenses $13,927,035 · Grants $6,601,315

  • See schedule O

    Expenses $5,232,718 · Grants $422,632

  • See schedule O

    Expenses $4,890,020 · Grants $627,673

  • Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa

    Expenses $22,071,233 · Grants $5,130,626

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • Ayoade Alakija

    CHAIRMAN OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • David Heymann

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Frutiger Christian

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Kamineni Shobana

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Marcel Tanner

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Michele Costaforlaz

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Precious Matsoso

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Rick Arthur Bright

    MEMBER OF THE BOARD (THRU 8/2024)

    Total calculated
    $0
    Hours/week
    1
  • Soumya Swaminathan

    MEMBER OF THE BOARD (THRU 8/2024)

    Total calculated
    $0
    Hours/week
    1
  • Cassandra Kelly-Cirino

    VP, HEALTH PROGRAMMES (thru 8/24)

    Total calculated
    $236,404
    From this org
    $191,471
    From related orgs
    $0
    Other
    $44,933
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $191,471
    Bonus
    $0
    Other
    $0
    Deferred
    $38,430
    Nontaxable benefits
    $6,503
    Filer's total
    $236,404
  • Dayo Adetifa

    CHIEF TRANSFORMATION OFFICER/CEO

    Total calculated
    $173,587
    From this org
    $138,966
    From related orgs
    $0
    Other
    $34,621
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $138,966
    Bonus
    $0
    Other
    $0
    Deferred
    $34,621
    Nontaxable benefits
    $0
    Filer's total
    $173,587
  • Marta Fernandez Suarez

    CHIEF TECHNOLOGY OFFICER (thru 10/24)

    Total calculated
    $356,565
    From this org
    $285,980
    From related orgs
    $0
    Other
    $70,585
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $285,980
    Bonus
    $0
    Other
    $0
    Deferred
    $56,899
    Nontaxable benefits
    $13,686
    Filer's total
    $356,565
  • Norma Torres

    CHIEF OPERATING OFFICER (thru 5/24)

    Total calculated
    $229,953
    From this org
    $215,973
    From related orgs
    $0
    Other
    $13,980
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $215,973
    Bonus
    $0
    Other
    $0
    Deferred
    $13,980
    Nontaxable benefits
    $0
    Filer's total
    $229,953
  • Sergio Carmona

    CHIEF MEDICAL OFFICER (thru 9/24)

    Total calculated
    $343,382
    From this org
    $284,240
    From related orgs
    $0
    Other
    $59,142
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $254,041
    Bonus
    $30,199
    Other
    $0
    Deferred
    $54,619
    Nontaxable benefits
    $4,523
    Filer's total
    $343,382
  • Sharon Saacks

    SENIOR DIRECTOR, PROGRAMME OPERATIONS (thru 7/24)

    Total calculated
    $269,143
    From this org
    $230,858
    From related orgs
    $0
    Other
    $38,285
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $145,852
    Bonus
    $0
    Other
    $85,006
    Deferred
    $38,285
    Nontaxable benefits
    $0
    Filer's total
    $269,143
  • William Rodriguez

    CHIEF EXECUTIVE OFFICER (thru 6/24)

    Total calculated
    $223,051
    From this org
    $197,568
    From related orgs
    $0
    Other
    $25,483
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $197,568
    Bonus
    $0
    Other
    $0
    Deferred
    $25,483
    Nontaxable benefits
    $0
    Filer's total
    $223,051
  • Willo Brock

    EXECUTIVE VP, EXTERNAL AFFAIRS (thru 6/24)

    Total calculated
    $163,705
    From this org
    $163,705
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $163,705
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $163,705
  • Darryl English

    DEPUTY DIRECTOR, FINANCE (THRU 11/24)

    Total calculated
    $414,021
    From this org
    $342,536
    From related orgs
    $0
    Other
    $71,485
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $342,536
    Bonus
    $0
    Other
    $0
    Deferred
    $71,485
    Nontaxable benefits
    $0
    Filer's total
    $414,021
  • Kevin Tetteh

    DIRECTOR, MALARIA FEVER PROGRAMME

    Total calculated
    $224,954
    From this org
    $181,958
    From related orgs
    $0
    Other
    $42,996
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $181,958
    Bonus
    $0
    Other
    $0
    Deferred
    $42,996
    Nontaxable benefits
    $0
    Filer's total
    $224,954
  • Sanjay Sarin

    VP, ACCESS (thru 10/24)

    Total calculated
    $232,372
    From this org
    $232,372
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $232,372
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $232,372
  • Beatrice Mouton

    DIRECTOR, HUMAN RESOURCES

    Total calculated
    $313,006
    From this org
    $260,701
    From related orgs
    $0
    Other
    $52,305
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $260,701
    Bonus
    $0
    Other
    $0
    Deferred
    $44,367
    Nontaxable benefits
    $7,938
    Filer's total
    $313,006
  • Brooke Nichols

    SENIOR DIRECTOR, IMPACT

    Total calculated
    $296,689
    From this org
    $265,429
    From related orgs
    $0
    Other
    $31,260
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $265,429
    Bonus
    $0
    Other
    $0
    Deferred
    $31,260
    Nontaxable benefits
    $0
    Filer's total
    $296,689
  • Maria Cecilia Ferreyra Arellano

    Director of AMR Programme

    Total calculated
    $250,024
    From this org
    $213,012
    From related orgs
    $0
    Other
    $37,012
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $213,012
    Bonus
    $0
    Other
    $0
    Deferred
    $30,675
    Nontaxable benefits
    $6,337
    Filer's total
    $250,024
  • Morten Ruhwald

    DIRECTOR, TUBERCULOSIS PROGRAMME

    Total calculated
    $298,773
    From this org
    $244,800
    From related orgs
    $0
    Other
    $53,973
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $244,800
    Bonus
    $0
    Other
    $0
    Deferred
    $44,029
    Nontaxable benefits
    $9,944
    Filer's total
    $298,773
  • Shaukhat Ali Khan

    Director Strategic Information

    Total calculated
    $289,581
    From this org
    $235,091
    From related orgs
    $0
    Other
    $54,490
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $235,091
    Bonus
    $0
    Other
    $0
    Deferred
    $44,098
    Nontaxable benefits
    $10,392
    Filer's total
    $289,581

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

  • 2024
    Revenue
    $49,306,331
    Expenses
    $56,828,646
    Contributions
    $46,591,810
    Grants paid
    $12,782,246
  • 2023
    Revenue
    $90,612,477
    Expenses
    $96,117,239
    Contributions
    $86,961,801
    Grants paid
    $35,829,203
  • 2022
    Revenue
    $144,248,069
    Expenses
    $146,186,498
    Contributions
    $142,991,509
    Grants paid
    $87,636,841

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $110,032,140
    Expenses
    $95,593,710
    Assets (EOY)
    $189,507,117
  • 2020 · 990

    Revenue
    $98,212,578
    Expenses
    $91,124,840
    Assets (EOY)
    $107,298,970

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

  • Biomeme

    $4,015,000

    2022 Development of diagnostic tests

  • Transnational TechnologiesInc

    $3,200,000

    2022 Supportmanufacturingandcommercializationof antigenrdtforcovid

  • WHO-PAHO

    $2,275,676

    2022 Scaling-uptheuseofcovidantigenrapiddiagnost ic tests in Americas testsinAmericas testsinAmericas

  • 2022 TosupportTBeliminationefforts

  • Diagnostic Consulting Network Inc

    $1,012,297

    2023 Development of diagnotic tests

  • DiagnosticConsultingNetworkInc

    $854,249

    2022 Developmentofdiagnostictests

  • Elizabeth Glaser Pediatric Aids Foundation

    $793,500

    2022 Evaluation of Antigen Rapid Diagnostic Tests

  • 2022 ImplementationofcovidagRDTsinSouthSudan

  • 2023 To support TB elimination efforts

  • Biomeme

    $685,000

    2023 Development of diagnotic tests

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

No itemized grant names this organization as a recipient. Only grants over $5,000 are itemized, and only by filers of the full Form 990.

Activities outside the United States

From Schedule F of the 2024 Form 990 , its newest Form 990 or 990-EZ that we hold. As filed.

Offices (line 3c)
3
Employees, agents and contractors (line 3c)
210
Expenditures and investments (line 3c)
$52,547,847

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
Sub-Saharan Africa 1 24 Program Services LABORATORY STRENGTHENING EVALUATION WORK $11,437,079
South Asia 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $2,838,911
East Asia and the Pacific 1 7 Program Services LABORATORY STRENGTHENING EVALUATION WORK $2,516,239
Europe (Including Iceland and Greenland) 1 179 Program Services LABORATORY STRENGTHENING EVALUATION WORK $34,190,111
South America 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $718,880
North America (Canada & Mexico only) 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $536,256
Russia and Neighboring States 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $78,098
Middle East and North Africa 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $191,790
Central America and the Caribbean 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $40,483

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
Sub-Saharan Africa $5,538,205 ELEC FD TRAN — N/A N/A
South Asia $204,033 ELEC FD TRAN — N/A N/A
East Asia and the Pacific $866,217 ELEC FD TRAN — N/A N/A
Europe (Including Iceland and Greenland) $4,581,949 ELEC FD TRAN — N/A N/A
South America $532,607 ELEC FD TRAN — N/A N/A
Russia and Neighboring States $54,879 ELEC FD TRAN — N/A N/A
Middle East and North Africa $27,033 ELEC FD TRAN — N/A N/A
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
52
Other grantees (Part II line 3)
57
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Declared on its 2024 return

  • FIND INDIA

    PROGRAM SERVICES · IN · controlled entity

  • FIND DX NPC

    PROGRAM SERVICES · SF · controlled entity

  • FIND DX KENYA

    PROGRAM SERVICES · KE · controlled entity

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Listed as of 11 November 2026, under deductibility FORGN.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 9 November 2026 and read 9 November 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.